The deal would have allowed the drug make own 51% stake in Cronus Pharma Specialities India.
On 12 August 2021, Aurobindo Pharma had announced the agreement to buy the majority stake in Cronus by subscribing to 95,059,963 equity shares of Rs 10 each, at a premium of Rs 34.18 per equity share, aggregating to Rs 420 crore.
"The Board of Directors at its meeting held today has approved the termination of aforesaid agreements and the paries have mutually agreed and terminated the said agreements," Aurobindo informed the BSE on Friday.
Aurobindo Pharma posted an 8.9% rise in consolidated net profit to Rs 770 crore on 2.9% rise in net sales to Rs 5,702 crore in Q1 FY22 over Q1 FY21.
Shares of Aurobindo Pharma rallied 4.37% to Rs 711.25 on BSE. Aurobindo Pharma headquartered at Hyderabad, India, develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU